Day One Biopharmaceuticals’ (DAWN) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a research report report published on Wednesday,Benzinga reports. They currently have a $32.00 price objective on the stock. Wedbush also issued estimates for Day One Biopharmaceuticals’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.41) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at $0.21 EPS and FY2028 earnings at $1.24 EPS.

Several other research analysts have also issued reports on DAWN. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. HC Wainwright reduced their target price on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday. Bank of America decreased their target price on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday. Finally, The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $34.86.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $9.06 on Wednesday. Day One Biopharmaceuticals has a 1 year low of $9.02 and a 1 year high of $18.07. The business’s 50-day moving average is $12.16 and its 200-day moving average is $13.38. The company has a market capitalization of $913.66 million, a price-to-earnings ratio of -8.80 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. Analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Charles N. York II sold 4,370 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares in the company, valued at $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,064 shares of company stock valued at $651,225. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. FMR LLC increased its stake in Day One Biopharmaceuticals by 73.9% in the 4th quarter. FMR LLC now owns 12,887,467 shares of the company’s stock valued at $163,284,000 after buying an additional 5,475,087 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,829,000. Braidwell LP increased its position in shares of Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after acquiring an additional 1,837,949 shares during the last quarter. Vestal Point Capital LP lifted its holdings in Day One Biopharmaceuticals by 100.0% during the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock worth $34,825,000 after acquiring an additional 1,250,000 shares during the period. Finally, Boxer Capital Management LLC bought a new stake in Day One Biopharmaceuticals during the fourth quarter worth $15,077,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.